Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07018492 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of BPN14770 in Participants With Hepatic Impairment and Healthy Controls
A Phase 1 study, sponsored by Shionogi.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT07018492 is a Phase 1 study that has completed, run by Shionogi. The registered enrollment target is 32 participants.
The verdict
NCT07018492, a Phase 1 study, has completed, sponsored by Shionogi.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The primary purpose of this study is to assess the pharmacokinetics (PK) of BPN14770 after a single oral administration of BPN14770 in participants with mild, moderate, and severe liver impairment compared with control participants with normal hepatic function.
Interventions
- DRUG BPN14770
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2025-08-30 |
| Est. Completion | 2025-11-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07018492
The ClinicalTrials.gov registry entry for NCT07018492 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shionogi, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BPN14770 is the first listed.
NCT07018492 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07018492 about?
NCT07018492 is a clinical study titled "Phase 1 Study of BPN14770 in Participants With Hepatic Impairment and Healthy Controls". The primary purpose of this study is to assess the pharmacokinetics (PK) of BPN14770 after a single oral administration of BPN14770 in participants with mild, moderate, and severe liver impairment compared with control participants with normal hepatic function.
What is the current status of trial NCT07018492?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2025-08-30. Estimated completion is 2025-11-26.
What interventions are being tested in trial NCT07018492?
The interventions under investigation include: BPN14770 (DRUG).
Who is sponsoring clinical trial NCT07018492?
This trial is sponsored by Shionogi, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.